68 related articles for article (PubMed ID: 37933203)
21. Myelomonocytic and monocytic acute myeloid leukemia demonstrate comparable poor outcomes with venetoclax-based treatment: a monocentric real-world study.
Zhao L; Yang J; Chen M; Xiang X; Ma H; Niu T; Gong Y; Chen X; Liu J; Wu Y
Ann Hematol; 2024 Apr; 103(4):1197-1209. PubMed ID: 38329487
[TBL] [Abstract][Full Text] [Related]
22. Molecular ontogeny underlies the benefit of adding venetoclax to hypomethylating agents in newly diagnosed AML patients.
Shimony S; Garcia JS; Keating J; Chen EC; Luskin MR; Stahl M; Neuberg DS; DeAngelo DJ; Stone RM; Lindsley RC
Leukemia; 2024 Mar; ():. PubMed ID: 38538860
[TBL] [Abstract][Full Text] [Related]
23. Does patient fitness play a role in determining first-line treatment of acute myeloid leukemia?
Chen EC; Garcia JS
Hematology Am Soc Hematol Educ Program; 2020 Dec; 2020(1):41-50. PubMed ID: 33275683
[TBL] [Abstract][Full Text] [Related]
24. Therapy with hypomethlyating agents/venetoclax in patients with newly diagnosed acute myeloid leukaemia requiring admission to the intensive care unit: Possible reduction in side effects with preserved efficacy.
Fiedler W
Br J Haematol; 2024 Apr; 204(4):1135-1136. PubMed ID: 38228122
[TBL] [Abstract][Full Text] [Related]
25. Proteomics for optimizing therapy in acute myeloid leukemia: venetoclax plus hypomethylating agents versus conventional chemotherapy.
de Camargo Magalhães ES; Hubner SE; Brown BD; Qiu Y; Kornblau SM
Leukemia; 2024 May; 38(5):1046-1056. PubMed ID: 38531950
[TBL] [Abstract][Full Text] [Related]
26. Outcomes of intermediate or high-risk CMML patients treated with hypomethylating agents combined with venetoclax: A single center experience.
Li C; Deng C; Wu P; Liu K; Huang X; Li M; Chen X; Geng S; Lai P; Weng J; Du X
Clin Transl Sci; 2024 Jan; 17(1):e13711. PubMed ID: 38129985
[TBL] [Abstract][Full Text] [Related]
27. [Efficacy and safety analysis of venetoclax combined with hypomethylating agents for the treatment of higher-risk myelodysplastic syndromes in the real world].
Gao QY; Li B; Qu SQ; Pan LJ; Jiao M; Zhao JY; Xu ZF; Xiao ZJ; Qin TJ
Zhonghua Xue Ye Xue Za Zhi; 2024 Feb; 45(2):156-162. PubMed ID: 38604792
[No Abstract] [Full Text] [Related]
28. Cardiac events in newly diagnosed acute myeloid leukaemia during treatment with venetoclax + hypomethylating agents.
Johnson IM; Karrar O; Rana M; Iftikhar M; Chen S; McCullough K; Saliba AN; Al-Kali A; Alkhateeb H; Begna K; Litzow M; Hogan WJ; Shah M; Patnaik MM; Pardanani A; Hermann J; Tefferi A; Gangat N
Br J Haematol; 2024 Apr; 204(4):1232-1237. PubMed ID: 38311378
[TBL] [Abstract][Full Text] [Related]
29. Cytogenetic and Molecular Associations with Outcomes in Higher-Risk Myelodysplastic Syndromes Treated with Hypomethylating Agents plus Venetoclax.
Bazinet A; Desikan SP; Li Z; Rodriguez-Sevilla JJ; Venugopal S; Urrutia S; Montalban-Bravo G; Sasaki K; Chien KS; Hammond D; Kanagal-Shamanna R; Ganan-Gomez I; Kadia TM; Borthakur G; DiNardo CD; Daver NG; Jabbour EJ; Ravandi F; Kantarjian H; Garcia-Manero G
Clin Cancer Res; 2024 Apr; 30(7):1319-1326. PubMed ID: 38300723
[TBL] [Abstract][Full Text] [Related]
30. Combination therapy with hypomethylating agents and venetoclax versus intensive induction chemotherapy in IDH1- or IDH2-mutant newly diagnosed acute myeloid leukemia-A multicenter cohort study.
Bewersdorf JP; Shimony S; Shallis RM; Liu Y; Berton G; Schaefer EJ; Zeidan AM; Goldberg A; Stein E; Marcucci G; Bystrom RP; Lindsley RC; Chen EC; Ramos J; Stein A; Pullarkat V; Aldoss I; DeAngelo DJ; Neuberg DS; Stone RM; Garciaz S; Ball B; Stahl M
Am J Hematol; 2024 May; ():. PubMed ID: 38751104
[No Abstract] [Full Text] [Related]
31. Venetoclax-based combinations for the treatment of newly diagnosed acute myeloid leukemia.
Othman TA; Azenkot T; Moskoff BN; Tenold ME; Jonas BA
Future Oncol; 2021 Aug; 17(23):2989-3005. PubMed ID: 34024158
[TBL] [Abstract][Full Text] [Related]
32. How we use venetoclax with hypomethylating agents for the treatment of newly diagnosed patients with acute myeloid leukemia.
Jonas BA; Pollyea DA
Leukemia; 2019 Dec; 33(12):2795-2804. PubMed ID: 31628431
[TBL] [Abstract][Full Text] [Related]
33. Tumor lysis syndrome in patients with acute myeloid leukemia treated with venetoclax and hypomethylating agents with or without dose ramp-up.
Khouderchah CJ; Benitez LL; Marini BL; Fraga M; Pettit K; Burke PW; Bixby DL; Perissinotti AJ
Leuk Lymphoma; 2024 Feb; 65(2):228-234. PubMed ID: 37933203
[TBL] [Abstract][Full Text] [Related]
34. Tumor lysis syndrome risk in outpatient versus inpatient administration of venetoclax and hypomethlators for acute myeloid leukemia.
Pelcovits A; Moore J; Bakow B; Niroula R; Egan P; Reagan JL
Support Care Cancer; 2021 Sep; 29(9):5323-5327. PubMed ID: 33661367
[TBL] [Abstract][Full Text] [Related]
35. Tumor lysis syndrome and infectious complications during treatment with venetoclax combined with azacitidine or decitabine in patients with acute myeloid leukemia.
Arora S; Zainaldin C; Bathini S; Gupta U; Worth S; Bachiashvili K; Bhatia R; Godby K; Jamy O; Rangaraju S; Diamond B; Oliver JD; Salzman D; Di Stasi A; Vachhani P
Leuk Res; 2022 Jun; 117():106844. PubMed ID: 35487134
[TBL] [Abstract][Full Text] [Related]
36. A phase 3b study of venetoclax and azacitidine or decitabine in an outpatient setting in patients with acute myeloid leukemia.
Manda S; Anz BM; Benton C; Broun ER; Yimer HA; Renshaw JS; Geils G; Berdeja J; Cruz J; Melear JM; Fanning S; Fletcher L; Li Y; Duan Y; Werner ME; Potluri J; Pai MV; Donnellan WB
Hematol Oncol; 2024 May; 42(3):e3274. PubMed ID: 38711253
[TBL] [Abstract][Full Text] [Related]
37.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
38.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
39.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
40.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]